论文部分内容阅读
目的 评价紫杉醇为主联合化疗治疗晚期卵巢癌患者的疗效和不良反应。方法 对25例晚期或复发性卵巢癌患者予以紫杉醇为主联合化疗。结果 初治组9例,CR1例,PR5例,总有效率为66.7％。复治组16例,PR6例,总有效率为37.5％。不良反应主要是骨髓抑制,特别是白细胞下降明显。结论 紫杉醇为主联合化疗对晚期卵巢癌应是首选的治疗方法。
Objective To evaluate the efficacy and adverse reactions of paclitaxel-based combination chemotherapy in patients with advanced ovarian cancer. Methods Twenty-five patients with advanced or recurrent ovarian cancer were treated with paclitaxel-based chemotherapy. Results The initial treatment group, 9 cases, CR1 cases, PR5 cases, the total effective rate was 66.7%. Retreatment group 16 cases, PR6 cases, the total effective rate was 37.5%. Adverse reactions are mainly myelosuppression, especially white blood cells decreased significantly. Conclusion paclitaxel-based combination chemotherapy for advanced ovarian cancer should be the preferred treatment.